Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain
Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead […]
Hansa Announces Global Pivotal Phase 3 Trial in Anti-GBM Disease
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced the first […]
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
Amplia Therapeutics is pleased to announce new data showing the efficacy of its investigational FAK […]
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer
Shattuck Labs, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a […]
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline […]
Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion Study in GBM Patients
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, has announced encouraging new data […]
Genome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical Trial
Genome Medical, the leading telehealth provider of genetic services and solutions, is teaming up with […]
Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004
Lynk Pharmaceuticals, an innovative clinical stage company, announced that it has dosed the first cohort […]
TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion
TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, […]
Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer
Topas Therapeutics, a clinical-stage biotech company developing novel antigen-specific immune tolerance therapies to treat autoimmune […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more